Evidence map›Paper›PMID 26101698›Full record

ArticleAmerican journal of cancer research2015

Heterogeneity of chemokine cell-surface receptor expression in triple-negative breast cancer.

Kerri-Ann Norton, Aleksander S Popel, Niranjan B Pandey

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kerri-Ann NortonDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University Baltimore, MD 21205, USA.
Aleksander S PopelDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University Baltimore, MD 21205, USA ; Department of Oncology and The Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University Baltimore, MD, USA.
Niranjan B PandeyDepartment of Biomedical Engineering, School of Medicine, Johns Hopkins University Baltimore, MD 21205, USA.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Predictive experiment-based multiscale models of the tumor immune microenvironment and immunotherapy in breast cancerR01CA138264 · NCI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2009 to 2023
$8.1M
Image-guided combination therapy: noninvasive assessment of delivery and responseR01CA154738 · NCI · JOHNS HOPKINS UNIVERSITY · PI ARTEMOV, DMITRI, BACKER, JOSEPH M · 2011 to 2015
$2.9M
NCI NIH HHS R01 CA138264NCI NIH HHS R01 CA154738
6 · The paper itself

Abstract

introductionTumor heterogeneity is a well-established concept in cancer research. In this paper, we examine an additional type of tumor cell heterogeneity - tumor cell-surface receptor heterogeneity.

methodsWe use flow cytometry to measure the frequency and numbers of cell-surface receptors on triple negative breast cancer cell lines.

resultsWe find two distinct populations of human triple-negative breast cancer cells MDA-MB-231 when they are grown in culture, one with low surface levels of various chemokine receptors and a second with much higher levels. The population with high surface levels of these receptors is increased in the more metastatic MDA-MB-231-luc-d3h2ln cell line.

conclusionWe hypothesize that this high cell-surface receptor population is involved in metastasis. We find that the receptor high populations can be modulated by tumor conditioned media and IL6 treatment indicating that the tumor microenvironment is important for the maintenance and sizes of these populations.

Indexed as

CCR5CXCR3CXCR4IL6MDA-MB-231stem cells

Identifiers

PMID26101698
PMCPMC4473311
OpenAlexW2406967909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.